ClinicalTrials.gg
Active, not recruitingNCT05654623VERITAC-2Updated Mar 18, 2026Results posted

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

A Phase 3 interventional study of ARV-471 and Fulvestrant in Advanced Breast Cancer, sponsored by Pfizer. Active, not recruiting at 312 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
624
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
2nd of 12
624 · median 48
Started
2023
with 5 others
Phase 3
2 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
8 of 12
Pfizer

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 2nd largest by enrollment, is one of 6 that started in 2023, is one of 2 in phase 3, and was the 8th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Read the detailed description

The purpose of this study is to learn about the safety and effects of the study medicine ARV-471 (PF-07850327, vepdegestrant) compared to fulvestrant (FUL) in participants with advanced breast cancer. Advanced breast cancer is difficult to cure or control with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body, i.e. bones, lungs, brain, or liver. FUL is a medicine already used for treatment of breast cancer while ARV-471 is a new medicine.

This study is seeking participants with breast cancer who:

  • have cancer that has come back in the place where it started or spread to nearby tissue, lymph nodes, or distant parts of the body.
  • cannot be fully cured by surgery or radiation therapy. Radiation therapy is the use of high-energy radiation such as x-rays, gamma rays and other sources to kill cancer cells and shrink tumors.
  • respond to hormonal or endocrine therapy (which target hormones and/or activity of hormone receptors) such as tamoxifen or aromatase inhibitors (this is called estrogen receptor positive disease)
  • have received one line of CDK4/6 inhibitor therapy (for example palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy (for example letrozole) for advanced cancer.
  • are allowed up to one other endocrine therapy (for example exemestane) for advanced cancer.

Half of the participants will be given ARV-471 while the other half of the participants will be given FUL.

Participants who get ARV-471 will take ARV-471 by mouth with food, one time a day. During the first treatment cycle participants who will get FUL will be given FUL by shots into the muscles on Day 1 and again 2 weeks later. After the first month, FUL shots will be given on the first day of each new treatment cycle. One treatment cycle is 28 days.

Participants will receive the study medicine until their breast cancer worsens or side effects become too severe. Participants will have visits at the study clinic about every 4 weeks.

03

Conditions studied

  • Advanced Breast Cancer

Browse trials for

Keywords

  • ER(+)/HER2(-) Advanced Breast Cancer
  • Advanced cancer of the breast
  • Breast neoplasm
  • Breast tumor
  • Breast cancer
  • Fulvestrant
  • Estrogen receptor positive
  • Metastatic breast cancer
  • ER degrader
  • PROTAC
  • Hormone Therapy
  • Hormone positive breast cancer
  • Endocrine therapy
  • Recurrent breast cancer
  • HR+
  • HER2-negative
  • Vepdegestrant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with loco-regional recurrent or breast disease not amenable to surgical resection or radiation therapy
  • Confirmed diagnosis of ER+/- breast cancer
  • Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:
  • One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.
  • ≤ 1 endocrine therapy in addition to CDK4/6 inhibitor with ET
  • Most recent endocrine treatment duration must have been given for ≥6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor .
  • Radiological progression during or after the last line of therapy.
  • evaluable per Response Evaluation Criterion in Solid Tumors () v.1.1 or non-measurable bone-only disease
  • (ECOG) performance status 0-1
  • Participants should be willing to provide blood and tumor tissue

Exclusion criteria

Exclusion Criteria:

  • Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term
  • Prior treatment with:
  • ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting
  • other agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting
  • prior chemotherapy for advanced/ disease
  • Inadequate liver, kidney and bone marrow function
  • Active
  • Participants with significant concomitant illness
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
624 participants (actual)

Study arms

  • Experimental
    ARV-471

    Drug: ARV-471

  • Active comparator
    Fulvestrant

    Drug: Fulvestrant

Interventions

  • orally, once daily on a 28-day continuous dosing schedule

    Also known as: PF-07850327

  • intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants

    PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

    Time frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

  2. PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation

    PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

    Time frame: From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

Secondary outcomes

  1. Overall Survival (OS)-All Randomized Participants

    OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

    Time frame: From date of randomization to the date of death due to any cause or censoring date

  2. OS-Participants With ESR1 Mutation

    OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

    Time frame: From date of randomization to the date of death due to any cause or censoring date

  3. Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline

    OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis \<10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

    Time frame: From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

  4. Clinical Benefit Rate (CBR) by BICR Assessment

    CBR: percentage of participants with clinical benefit response. Clinical benefit response: confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks per RECIST v1.1. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions assessed. SD: did not qualify for CR, PR, PD. All target lesions assessed. PD per RECIST v1.1: at least 20% increased sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to timepoint under evaluation), with minimum absolute increase of 5mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

    Time frame: From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

  5. Duration of Response (DOR) by BICR Assessment

    DOR was defined as time from first documentation of objective tumor response (CR or PR) to first documentation of PD, or death due to any cause, whichever occurred first. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions were assessed. The short diameter is used in the sum for nodal target lesions, while longest diameter is used in sum for non-nodal target lesions, all target lesions were assessed. DOR was analyzed in participants with an OR. PD: at least 20% increase in sum of diameters of target measurable lesions above nadir, with minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

    Time frame: From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

  6. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs, Grade 3 or 4 and Grade 5 TEAEs as Assessed by NCI CTCAE v5.0

    Adverse event (AE): any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. AEs included both SAEs and all other (non-SAEs) AEs. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. TEAEs: AEs that occur on or after first dose of study treatment up to 28 days after last dose of study treatment. Relatedness to study drug were judged by investigator. As per National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) severity of AEs were graded as following, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening; urgent treatment indicated, Grade 5: death related to AE.

    Time frame: From the first dose of study treatment up to 28 days after last dose of study treatment

  7. Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE v5.0

    Hematological parameters including neutrophil count decreased, white blood cell decreased, anemia, platelet count decreased, hemoglobin increased and leukocytosis were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0, severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

    Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

  8. Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE v5.0

    Serum chemistry parameters including alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0 severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that falls outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

    Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

  9. Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters

    Twelve lead ECGs were collected using an automated ECG machine that calculated heart rate and measured corrected QT (QTc interval, QT interval, PR interval and QRS complex). Criteria for heart rate was as follows, \<= 50 beats/minute (min), \>=100 beats/min, increase from baseline \>= 20 beats/min, decrease from baseline \>= 20 beats/min. Criteria for PR interval was \>= 220 millisecond (msec). Criteria for QRS interval was \>= 120 msec. Criteria for QT interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \>480 to \<=500 msec, \>500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec. Criteria for QTCF interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \> 480 to \<= 500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

    Time frame: From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

  10. Number of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set

    Criteria for QTcF interval for single beat were as follows, \<= 450 msec, \> 450 to \<= 480 msec, \> 480 to \<=500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

    Time frame: Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)

  11. Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire (EORTC QLQ-C30) Score

    The EORTC QLQ-C30 contains 30 items and is composed of 5 multi-item functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 3 multi-item symptom scales (fatigue, pain and nausea/vomiting), 6 single item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and one global quality of life scale. This questionnaire contained 30 questions organized into 5 multi-item functional scales, 3 multi-item symptom scales, 6 single item symptom scales, and one global quality of life scale. All the scales and single-item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.

    Time frame: From baseline up to 28 days after last dose of study treatment

  12. Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire-Breast Cancer Specific (EORTC QLQ-BR23) Score

    The EORTC QLQ-BR23 was a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consisted of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated by choosing 1 of 4 possible responses that record the level of intensity (1= not at all, 2= a little, 3= quite a bit, and 4= very much) within each scale. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. For symptom-oriented scales, higher scores represented greater symptom severity.

    Time frame: From baseline up to 28 days after last dose of study treatment

  13. Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and Visual Analogue Scale (VAS) Scores

    The EQ-5D-5L was a 5-item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score. There were 2 components, a Health State Profile where participants rated their level of problems (1=none, 2=slight, 3=moderate, 4=severe, 5=extreme/unable) in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (VAS) in which participants rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Responses to 5 dimensions comprised health state/ single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had a unique predefined utility index value assigned to it per US value sets, Overall index scores ranged from 0 to 1, with lower scores representing a higher level of dysfunction.

    Time frame: From baseline up to 28 days after last dose of study treatment

  14. Change From Baseline in Pain Severity and Pain Interference as Assessed by Brief Pain Inventory Short Form (BPI-SF) Score

    The BPI-SF consisted of items to measure participant perceptions of pain severity (item 3), assess degree of interference of pain on daily functioning, body diagrams on which participants indicate location of pain, record pain medication usage, VAS assessed degree of pain relief in last 24 hours (item 9a). Items in pain severity scale evaluated pain "at its worst", "at its least", and "on average" over previous 24 hours, as well as "pain now" (at time of assessment). Participants responded on 10- point numerical rating scale, where 0 = "no pain" and 10 = "pain as bad as you can imagine". Pain interference scale asked participants to rate how their pain interferes with "enjoyment of life", "general activity", "walking ability", "mood", "sleep", "normal work" and "relations with other people." Responses for interference scale were also based on 10-points scale, where 0 = "does not interfere" and 10 = "interferes completely". Higher scores=high levels of pain, impact attributed to pain.

    Time frame: From baseline up to 28 days after last dose of study treatment

  15. Plasma Concentration of ARV-471 and Its Epimer ARV-473

    Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

    Time frame: Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3

  16. Change in Plasma Circulating Tumor DNA (ctDNA) From Baseline

    Quantitative change in plasma ctDNA levels from baseline to each protocol specified time point (up to EOT), as assessed using a validated assay.

    Time frame: Baseline and up to EOT

07

Results

Posted Feb 3, 2026

Participant flow

Participants with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 negative (HER2-) unresectable locoregional recurrent or metastatic breast cancer (mBC) not amenable to radiotherapy with curative intent who progressed after prior endocrine based treatment(s) for advanced disease were included in this study.

Treatment
Participant flow — Treatment
MilestoneVepdegestrant (ARV-471)Fulvestrant
Started313311
Treated312307
Completed00
Not completed313311
Withdrew: Randomized but not treated14
Withdrew: Adverse event72
Withdrew: Death20
Withdrew: Physician decision23
Withdrew: Progressive disease189209
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject97
Withdrew: Global deterioration of health status59
Withdrew: Other01
Withdrew: Ongoing9676
Follow-up
Participant flow — Follow-up
MilestoneVepdegestrant (ARV-471)Fulvestrant
Started205224
Completed00
Not completed205224
Withdrew: Death4335
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject12
Withdrew: Ongoing161186

Outcome measures

PrimaryProgression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants

PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

Time frame:
From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Reported as:
Median · Months
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants
MonthsVepdegestrantFulvestrant
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants3.7 (3.6 to 5.3)3.6 (2.2 to 3.8)
Statistical analysis
  • Vepdegestrant vs Fulvestrant · Log Rank · p = 0.0358 · Hazard ratio (hr): 0.83 · 95% CI 0.676 to 1.016HR was calculated based on Cox's Proportional Hazard model.
PrimaryPFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation

PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

Time frame:
From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Reported as:
Median · Months
PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation
MonthsVepdegestrantFulvestrant
PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation5.0 (3.7 to 7.4)2.1 (1.9 to 3.5)
Statistical analysis
  • Vepdegestrant vs Fulvestrant · Log Rank · p = 0.0001 · Hazard ratio (hr): 0.57 · 95% CI 0.418 to 0.770HR was calculated based on Cox's Proportional Hazard model.
SecondaryOverall Survival (OS)-All Randomized Participants

OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

Time frame:
From date of randomization to the date of death due to any cause or censoring date

Results for this outcome have not been posted.

SecondaryOS-Participants With ESR1 Mutation

OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

Time frame:
From date of randomization to the date of death due to any cause or censoring date

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline

OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis \<10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

Time frame:
From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline
Percentage of participantsVepdegestrantFulvestrant
Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline10.9 (7.4 to 15.6)3.6 (1.8 to 6.9)
SecondaryClinical Benefit Rate (CBR) by BICR Assessment

CBR: percentage of participants with clinical benefit response. Clinical benefit response: confirmed CR or PR at any time, or stable disease (SD) \>=24 weeks per RECIST v1.1. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions assessed. SD: did not qualify for CR, PR, PD. All target lesions assessed. PD per RECIST v1.1: at least 20% increased sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to timepoint under evaluation), with minimum absolute increase of 5mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

Time frame:
From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) by BICR Assessment
Percentage of participantsVepdegestrantFulvestrant
Clinical Benefit Rate (CBR) by BICR Assessment34.3 (28.9 to 40.1)28.7 (23.6 to 34.3)
SecondaryDuration of Response (DOR) by BICR Assessment

DOR was defined as time from first documentation of objective tumor response (CR or PR) to first documentation of PD, or death due to any cause, whichever occurred first. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis \<10 mm); all disease sites, all target lesions assessed. PR: \>=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions were assessed. The short diameter is used in the sum for nodal target lesions, while longest diameter is used in sum for non-nodal target lesions, all target lesions were assessed. DOR was analyzed in participants with an OR. PD: at least 20% increase in sum of diameters of target measurable lesions above nadir, with minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

Time frame:
From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Reported as:
Median · Months
Duration of Response (DOR) by BICR Assessment
MonthsVepdegestrantFulvestrant
Duration of Response (DOR) by BICR AssessmentNA (5.6 to NA)7.4 (5.6 to NA)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs, Grade 3 or 4 and Grade 5 TEAEs as Assessed by NCI CTCAE v5.0

Adverse event (AE): any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. AEs included both SAEs and all other (non-SAEs) AEs. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. TEAEs: AEs that occur on or after first dose of study treatment up to 28 days after last dose of study treatment. Relatedness to study drug were judged by investigator. As per National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) severity of AEs were graded as following, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening; urgent treatment indicated, Grade 5: death related to AE.

Time frame:
From the first dose of study treatment up to 28 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryNumber of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE v5.0

Hematological parameters including neutrophil count decreased, white blood cell decreased, anemia, platelet count decreased, hemoglobin increased and leukocytosis were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0, severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

Time frame:
From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE v5.0
ParticipantsVepdegestrant (ARV-471)Fulvestrant
Neutrophil count decreased Grade 0 to Grade 13313
Neutrophil count decreased Grade 0 to Grade 22615
Neutrophil count decreased Grade 0 to Grade 340
Neutrophil count decreased Grade 0 to Grade 411
Neutrophil count decreased Grade 1 to Grade 059
Neutrophil count decreased Grade 1 to Grade 253
Neutrophil count decreased Grade 1 to Grade 311
Neutrophil count decreased Grade 2 to Grade 021
Neutrophil count decreased Grade 3 to Grade 201
White blood cell decreased Grade 0 to Grade 16831
White blood cell decreased Grade 0 to Grade 2188
White blood cell decreased Grade 0 to Grade 311
White blood cell decreased Grade 1 to Grade 01012
White blood cell decreased Grade 1 to Grade 2102
White blood cell decreased Grade 1 to Grade 301
White blood cell decreased Grade 2 to Grade 023
White blood cell decreased Grade 2 to Grade 101
Anemia Grade 0 to Grade 13833
Anemia Grade 0 to Grade 266
Anemia Grade 0 to Grade 311
Anemia Grade 1 to Grade 01412
Anemia Grade 1 to Grade 21711
Anemia Grade 1 to Grade 344
Anemia Grade 2 to Grade 011
Anemia Grade 2 to Grade 153
Anemia Grade 2 to Grade 325
Platelet count decreased Grade 0 to Grade 12522
Platelet count decreased Grade 0 to Grade 223
Platelet count decreased Grade 0 to Grade 322
Platelet count decreased Grade 1 to Grade 031
Platelet count decreased Grade 1 to Grade 201
Platelet count decreased Grade 1 to Grade 310
Hemoglobin increased Grade 0 to Grade 183
Hemoglobin increased Grade 0 to Grade 210
SecondaryNumber of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE v5.0

Serum chemistry parameters including alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0 severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that falls outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

Time frame:
From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE v5.0
ParticipantsVepdegestrant (ARV-471)Fulvestrant
Alanine aminotransferase increased Grade 0 to Grade 15550
Alanine aminotransferase increased Grade 0 to Grade 265
Alanine aminotransferase increased Grade 0 to Grade 320
Alanine aminotransferase increased Grade 1 to Grade 05272
Alanine aminotransferase increased Grade 1 to Grade 234
Alanine aminotransferase increased Grade 1 to Grade 303
Alanine aminotransferase increased Grade 2 to Grade 069
Alanine aminotransferase increased Grade 2 to Grade 110
Alkaline phosphatase increased Grade 0 to Grade 15153
Alkaline phosphatase increased Grade 0 to Grade 215
Alkaline phosphatase increased Grade 1 to Grade 05352
Alkaline phosphatase increased Grade 1 to Grade 287
Alkaline phosphatase increased Grade 2 to Grade 003
Alkaline phosphatase increased Grade 2 to Grade 101
Alkaline phosphatase increased Grade 2 to Grade 301
Aspartate aminotransferase increased Grade 0 to Grade 17854
Aspartate aminotransferase increased Grade 0 to Grade 224
Aspartate aminotransferase increased Grade 0 to Grade 301
Aspartate aminotransferase increased Grade 1 to Grade 07684
Aspartate aminotransferase increased Grade 1 to Grade 245
Aspartate aminotransferase increased Grade 1 to Grade 354
Aspartate aminotransferase increased Grade 2 to Grade 062
Aspartate aminotransferase increased Grade 2 to Grade 103
Aspartate aminotransferase increased Grade 3 to Grade 001
Blood bilirubin increased Grade 0 to Grade 13012
Blood bilirubin increased Grade 0 to Grade 297
Blood bilirubin increased Grade 0 to Grade 313
Blood bilirubin increased Grade 0 to Grade 420
Blood bilirubin increased Grade 1 to Grade 004
Blood bilirubin increased Grade 1 to Grade 210
Blood bilirubin increased Grade 1 to Grade 301
Blood bilirubin increased Grade 2 to Grade 010
Cholesterol high Grade 0 to Grade 12231
Cholesterol high Grade 1 to Grade 02320
Cholesterol high Grade 1 to Grade 236
Cholesterol high Grade 1 to Grade 301
Cholesterol high Grade 2 to Grade 010
Cholesterol high Grade 2 to Grade 140
Creatinine increased Grade 0 to Grade 12622
Creatinine increased Grade 0 to Grade 289
Creatinine increased Grade 0 to Grade 301
Creatinine increased Grade 1 to Grade 086
Creatinine increased Grade 1 to Grade 220
Creatinine increased Grade 1 to Grade 301
Creatinine increased Grade 2 to Grade 101
Hypercalcemia Grade 0 to Grade 12421
Hypercalcemia Grade 0 to Grade 220
Hypercalcemia Grade 0 to Grade 310
Hypercalcemia Grade 0 to Grade 410
Hypercalcemia Grade 1 to Grade 043
Hypercalcemia Grade 1 to Grade 210
Hypercalcemia Grade 1 to Grade 301
Hypercalcemia Grade 1 to Grade 411
Hyperkalemia Grade 0 to Grade 12124
Hyperkalemia Grade 0 to Grade 243
Hyperkalemia Grade 1 to Grade 065
Hyperkalemia Grade 1 to Grade 210
Hypermagnesemia Grade 0 to Grade 1109
Hypermagnesemia Grade 0 to Grade 310
Hypermagnesemia Grade 1 to Grade 023
Hypermagnesemia Grade 3 to Grade 101
Hypernatremia Grade 0 to Grade 1114
Hypernatremia Grade 0 to Grade 210
Hypernatremia Grade 1 to Grade 011
Hypertriglyceridemia Grade 0 to Grade 14136
Hypertriglyceridemia Grade 0 to Grade 222
Hypertriglyceridemia Grade 0 to Grade 310
Hypertriglyceridemia Grade 1 to Grade 01911
Hypertriglyceridemia Grade 1 to Grade 295
Hypertriglyceridemia Grade 1 to Grade 320
Hypertriglyceridemia Grade 2 to Grade 001
Hypertriglyceridemia Grade 2 to Grade 131
Hypertriglyceridemia Grade 2 to Grade 301
Hypertriglyceridemia Grade 3 to Grade 401
Hypoalbuminemia Grade 0 to Grade 14032
Hypoalbuminemia Grade 0 to Grade 258
Hypoalbuminemia Grade 1 to Grade 048
Hypoalbuminemia Grade 1 to Grade 213
Hypoalbuminemia Grade 1 to Grade 301
Hypoalbuminemia Grade 2 to Grade 010
Hypoalbuminemia Grade 2 to Grade 110
Hypoalbuminemia Grade 2 to Grade 301
Hypocalcemia Grade 0 to Grade 12620
Hypocalcemia Grade 0 to Grade 213
Hypocalcemia Grade 0 to Grade 301
Hypocalcemia Grade 1 to Grade 055
Hypocalcemia Grade 1 to Grade 241
Hypocalcemia Grade 2 to Grade 110
Hypoglycemia Grade 0 to Grade 169
Hypoglycemia Grade 0 to Grade 210
Hypoglycemia Grade 1 to Grade 021
Hypokalemia Grade 0 to Grade 23218
Hypokalemia Grade 0 to Grade 340
Hypokalemia Grade 2 to Grade 001
Hypokalemia Grade 2 to Grade 330
Hypokalemia Grade 3 to Grade 001
Hypomagnesemia Grade 0 to Grade 11912
Hypomagnesemia Grade 0 to Grade 220
Hypomagnesemia Grade 1 to Grade 031
Hypomagnesemia Grade 1 to Grade 220
Hypomagnesemia Grade 2 to Grade 310
Hyponatremia Grade 0 to Grade 13432
Hyponatremia Grade 0 to Grade 342
Hyponatremia Grade 1 to Grade 078
Hyponatremia Grade 1 to Grade 310
Hyponatremia Grade 3 to Grade 010
Hyponatremia Grade 3 to Grade 101
SecondaryNumber of Participants According to Categorization of Electrocardiogram (ECG) Parameters

Twelve lead ECGs were collected using an automated ECG machine that calculated heart rate and measured corrected QT (QTc interval, QT interval, PR interval and QRS complex). Criteria for heart rate was as follows, \<= 50 beats/minute (min), \>=100 beats/min, increase from baseline \>= 20 beats/min, decrease from baseline \>= 20 beats/min. Criteria for PR interval was \>= 220 millisecond (msec). Criteria for QRS interval was \>= 120 msec. Criteria for QT interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \>480 to \<=500 msec, \>500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec. Criteria for QTCF interval was as follows, \<=450 msec, \> 450 to \<= 480 msec, \> 480 to \<= 500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

Time frame:
From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters
ParticipantsVepdegestrant (ARV-471)Fulvestrant
Heart rate <= 50 beats/min41
Heart rate >= 100 beats/min2319
Heart rate increase from baseline >=20 beats/min1715
Heart rate decrease from baseline >=20 beats/min2210
PR interval >= 220 msec44
QRS interval >=120 msec610
QT interval <=450 msec232278
QT interval >450 to <=480 msec5319
QT interval >480 to <=500 msec164
QT interval > 500 msec80
QT intervals increase from baseline <= 30 msec171267
QT intervals increase from baseline > 30 to <=60 msec11128
QT intervals increase from baseline > 60 msec266
QTcF interval <=450 msec177260
QTcF interval >450 to <=480 msec11638
QTcF interval >480 to <=500 msec111
QTcF interval > 500 msec52
QTcF interval increase from baseline <= 30 msec228291
QTcF interval increase from baseline > 30 to <= 60 msec719
QTcF interval increase from baseline > 60 msec81
SecondaryNumber of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set

Criteria for QTcF interval for single beat were as follows, \<= 450 msec, \> 450 to \<= 480 msec, \> 480 to \<=500 msec, \> 500 msec, increase from baseline \<= 30 msec, increase from baseline \> 30 to \<= 60 msec, increase from baseline \> 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

Time frame:
Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)
Reported as:
Count of participants · Participants
Number of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set
ParticipantsVepdegestrant (ARV-471)
QTcF interval for single beat <=450 msec63
QTcF interval for single beat > 450 to <= 480 msec24
QTcF interval for single beat >480 to <=500 msec0
QTcF interval for single beat > 500 msec1
QTcF interval for single beat increase from baseline <= 30 msec67
QTcF interval for single beat increase from baseline >30 to <= 60 msec21
QTcF interval for single beat increase from baseline > 60 msec0
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire (EORTC QLQ-C30) Score

The EORTC QLQ-C30 contains 30 items and is composed of 5 multi-item functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 3 multi-item symptom scales (fatigue, pain and nausea/vomiting), 6 single item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and one global quality of life scale. This questionnaire contained 30 questions organized into 5 multi-item functional scales, 3 multi-item symptom scales, 6 single item symptom scales, and one global quality of life scale. All the scales and single-item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.

Time frame:
From baseline up to 28 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire-Breast Cancer Specific (EORTC QLQ-BR23) Score

The EORTC QLQ-BR23 was a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consisted of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated by choosing 1 of 4 possible responses that record the level of intensity (1= not at all, 2= a little, 3= quite a bit, and 4= very much) within each scale. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. For symptom-oriented scales, higher scores represented greater symptom severity.

Time frame:
From baseline up to 28 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryChange From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and Visual Analogue Scale (VAS) Scores

The EQ-5D-5L was a 5-item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score. There were 2 components, a Health State Profile where participants rated their level of problems (1=none, 2=slight, 3=moderate, 4=severe, 5=extreme/unable) in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (VAS) in which participants rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Responses to 5 dimensions comprised health state/ single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had a unique predefined utility index value assigned to it per US value sets, Overall index scores ranged from 0 to 1, with lower scores representing a higher level of dysfunction.

Time frame:
From baseline up to 28 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryChange From Baseline in Pain Severity and Pain Interference as Assessed by Brief Pain Inventory Short Form (BPI-SF) Score

The BPI-SF consisted of items to measure participant perceptions of pain severity (item 3), assess degree of interference of pain on daily functioning, body diagrams on which participants indicate location of pain, record pain medication usage, VAS assessed degree of pain relief in last 24 hours (item 9a). Items in pain severity scale evaluated pain "at its worst", "at its least", and "on average" over previous 24 hours, as well as "pain now" (at time of assessment). Participants responded on 10- point numerical rating scale, where 0 = "no pain" and 10 = "pain as bad as you can imagine". Pain interference scale asked participants to rate how their pain interferes with "enjoyment of life", "general activity", "walking ability", "mood", "sleep", "normal work" and "relations with other people." Responses for interference scale were also based on 10-points scale, where 0 = "does not interfere" and 10 = "interferes completely". Higher scores=high levels of pain, impact attributed to pain.

Time frame:
From baseline up to 28 days after last dose of study treatment

Results for this outcome have not been posted.

SecondaryPlasma Concentration of ARV-471 and Its Epimer ARV-473

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

Time frame:
Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3
Reported as:
Median · Nanograms per milliliter
Plasma Concentration of ARV-471 and Its Epimer ARV-473
Nanograms per milliliterVepdegestrant (ARV-471)
ARV-471: Cycle 2 Day 1 (-4 to 0 hours)445.5 (3.05 to 1530)
ARV-471: Cycle 2 Day 1 (5 to 7 hours)795.5 (50.5 to 2260)
ARV-471: Cycle 3 Day 1 (-4 to 0 hours)453.5 (11.5 to 1680)
ARV-471: Cycle 3 Day 1 (5 to 7 hours)743.0 (151 to 2170)
ARV-471: Cycle 5 Day 1 (-4 to 0 hours)440.5 (0.00 to 1370)
ARV-471: Cycle 7 Day 1 (-4 to 0 hours)466.0 (18.7 to 1130)
ARV-473: Cycle 2 Day 1 (-4 to 0 hours)193.5 (0.00 to 628)
ARV-473: Cycle 2 Day 1 (5 to 7 hours)225.5 (19.3 to 700)
ARV-473: Cycle 3 Day 1 (-4 to 0 hours)193.0 (6.10 to 611)
ARV-473: Cycle 3 Day 1 (5 to 7 hours)214.0 (26.0 to 655)
ARV-473: Cycle 5 Day 1 (-4 to 0 hours)188.0 (0.00 to 561)
ARV-473: Cycle 7 Day 1 (-4 to 0 hours)186.0 (10.3 to 464)
SecondaryChange in Plasma Circulating Tumor DNA (ctDNA) From Baseline

Quantitative change in plasma ctDNA levels from baseline to each protocol specified time point (up to EOT), as assessed using a validated assay.

Time frame:
Baseline and up to EOT

Results for this outcome have not been posted.

Adverse events

Collected over Adverse events: From the first dose of study treatment up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively); All-cause mortality: From randomization until date of death due to any cause (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vepdegestrant (ARV-471)45/313 (14.4%)32/312 (10.3%)233/312 (74.7%)
Fulvestrant35/311 (11.3%)28/307 (9.1%)174/307 (56.7%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventVepdegestrant (ARV-471)Fulvestrant
Disease progressionGeneral disorders4/3121/307
VomitingGastrointestinal disorders0/3123/307
AnaemiaBlood and lymphatic system disorders0/3122/307
FallInjury, poisoning and procedural complications2/3122/307
PneumoniaInfections and infestations2/3121/307
Femoral neck fractureInjury, poisoning and procedural complications2/3121/307
Lumbar vertebral fractureInjury, poisoning and procedural complications2/3120/307
HypercalcaemiaMetabolism and nutrition disorders2/3121/307
ArrhythmiaCardiac disorders0/3121/307
Atrial fibrillationCardiac disorders0/3121/307
Most frequent other events
Showing 10 of 25
Most frequent other events
EventVepdegestrant (ARV-471)Fulvestrant
FatigueGeneral disorders49/31223/307
Alanine aminotransferase increasedInvestigations45/31230/307
Aspartate aminotransferase increasedInvestigations45/31232/307
NauseaGastrointestinal disorders42/31227/307
AnaemiaBlood and lymphatic system disorders36/31221/307
AstheniaGeneral disorders35/31226/307
ArthralgiaMusculoskeletal and connective tissue disorders33/31233/307
Decreased appetiteMetabolism and nutrition disorders33/31216/307
Back painMusculoskeletal and connective tissue disorders33/31220/307
ConstipationGastrointestinal disorders31/31210/307

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vepdegestrant (ARV-471)FulvestrantTotal
Mean60.3 ± 12.0960.3 ± 11.5260.3 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Vepdegestrant (ARV-471)FulvestrantTotal
Female311310621
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vepdegestrant (ARV-471)FulvestrantTotal
Hispanic or Latino293665
Not Hispanic or Latino241240481
Unknown or Not Reported433578
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vepdegestrant (ARV-471)FulvestrantTotal
American Indian or Alaska Native145
Asian122129251
Native Hawaiian or Other Pacific Islander000
Black or African American5611
White148143291
More than one race000
Unknown or Not Reported372966
08

Study locations

312 sites

Showing the first 100 of 312 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31. PubMed 40454645 ↗
  • Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. Epub 2024 Jul 29. PubMed 39072356 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jan 2025, 22 months.

Results were first posted in Feb 2026, 1 year after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 22 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Dec 16, 2022
StartActual
Mar 3, 2023
Primary completionActual
Jan 31, 2025
CompletionEst.
May 15, 2028
Results first posted
Feb 3, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05654623
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Dec 16, 2022
Start date
Mar 3, 2023
Primary completion
Jan 31, 2025
Completion
May 15, 2028 (estimated)
Results posted
Feb 3, 2026
Last update
Mar 18, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vepdegestrant

Start the discussion